0001104659-25-094111 Sample Contracts
EQUITY ISSUANCE AND REGISTRATION RIGHTS AGREEMENTEquity Issuance and Registration Rights Agreement • September 29th, 2025 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • New York
This Equity Issuance and Registration Rights Agreement (this “Agreement”) is dated as of September 29, 2025, by and between Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”), Serpin Pharma, Inc., a Delaware corporation (“Serpin Pharma”) and Rejuvenation Labs, Inc., a Delaware corporation (“Rejuvenation Labs” and, together with Serpin Pharma, “Serpin”).
Dogwood therapeutics, inc. SUPPORT AGREEMENTSupport Agreement • September 29th, 2025 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of September 29, 2025 (the “Effective Date”), is made by and between Dogwood Therapeutics, Inc., a Delaware corporation (“Dogwood”) and Sealbond Limited, a British Virgin Island corporation (“Sealbond”).
Dogwood therapeutics, inc. SUPPORT AGREEMENTSupport Agreement • September 29th, 2025 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of September 29, 2025 (the “Effective Date”), is made by and among Dogwood Therapeutics, Inc., a Delaware corporation (“Dogwood”), and each of the Persons set for on the signature page hereto (each, a “Holder”).
Dogwood therapeutics, inc. SUPPORT AGREEMENTSupport Agreement • September 29th, 2025 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of September 29, 2025 (the “Effective Date”), is made by and between Dogwood Therapeutics, Inc., a Delaware corporation (“Dogwood”) and [_______].
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 29th, 2025 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (“Agreement”) is made and entered into effective as of September 29, 2025 (“Effective Date”), by and between Serpin Pharma, Inc., a Delaware corporation (“Serpin”), and Dogwood Therapeutics, Inc., a Delaware corporation (“Dogwood”).